

DIASORIN AND TECAN TO COLLABORATE IN NEW PLATFORM DEVELOPMENT

June 23, 2017 - Saluggia, Italy and Männedorf, Switzerland - **DiaSorin** (FTSE Italy Mid Cap: DIA) and **Tecan Group** (SIX Swiss Exchange: TECN) announced today that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan's Fluent® Laboratory Automation Solution as its Nucleic Acid extraction platform.

The new platform will be used in combination with the DiaSorin LIAISON® MDX PCR system to provide the customer with a complete sample to result system for Molecular Diagnostics.

The Fluent platform, to be supplied through Tecan Partnering, will be optimized for use with DiaSorin extraction chemistry and automated PCR set up of the LIAISON® MDX 96 well disc.

Fluent breaks new ground, delivering more capacity and increased speed. The platform provides exceptional precision, throughput and walkaway time.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: *"The collaboration with Tecan for the development of this new platform sets the basis for further growth steps in the Molecular Diagnostic area. We are targeting interesting opportunities for our new molecular business, leveraging on the solid, innovative and versatile technology provided by our LIAISON MDX system"*.

Additional Information

Any additional information will be provided in the management presentation during the new DiaSorin Investor Day that will be held in Milan on June 26th, 2017 at 2.30 p.m. CET, 1.30 p.m. GMT, 8.30 a.m. US Eastern time.

Live streaming will be available only upon registration via e-mail to ir@diasorin.it

A replay and the transcript will be available after the event in the Investor Relations section at www.diasorin.com.

The official invitation is also available on the DiaSorin website in the Investor Relations section at www.diasorin.com



The Diagnostic Specialist



Press Release

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD "diagnostics specialist".

For more information, please visit www.diasorin.com

About TECAN

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2016, Tecan generated sales of CHF 506 million (USD 511 million; EUR 464 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For additional information, please contact

For DiaSorin

Riccardo Fava

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it

For TECAN

Martin Braendle

Vice President, Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com